This study is being conducted to assess the safety and tolerability of an oral liquid solution of Sustiva for antiretroviral therapy-naive or therapy-experienced HIV-1 infected children between the ages 3-16 who are failing or intolerant of current antiretroviral regimen and who are unable to swallow Sustiva capsules.
Study Type
EXPANDED_ACCESS
Oral Solution, Oral 200 - 600 mg (weight based), once daily. Until further treatment with Sustiva Oral Solution is not warranted.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Local Institution
Phoenix, Arizona, United States
Lac & Usc Medical Center
Los Angeles, California, United States
Local Institution
Washington D.C., District of Columbia, United States
Children'S Diagnostic Treatment Center
Fort Lauderdale, Florida, United States
Arnold Palmer Hospital For Children And Woman
Orlando, Florida, United States
Cleveland Clinic Florida
Weston, Florida, United States
The Children'S Memorial Hospital
Chicago, Illinois, United States
University Of Chicago
Chicago, Illinois, United States
Lsu Health Sciences Center
New Orleans, Louisiana, United States
Children'S Hospital
Boston, Massachusetts, United States
...and 19 more locations